PharmcoRx Pharmacy Launches Mark Cuban Cost Plus Drug Program Expanding Its In-Pharmacy Offerings
PharmcoRx Pharmacy, a wholly-owned subsidiary of Progressive Care Inc (OTCQB:RXMD), has announced a significant expansion of its in-pharmacy offerings through a strategic agreement with the Mark Cuban Cost Plus Drug Company (“Cost Plus Drugs”). This collaboration allows PharmcoRx to provide patients with the opportunity to purchase generic and branded medicines at their actual cost plus a low fixed markup.
The Mark Cuban Cost Plus Drug Company (“MCCPDC”) operates on a unique model, offering over 1,000 drugs at their true acquisition cost plus a transparent 15% markup. Recently, MCCPDC launched the Team Cuban Card, a free prescription benefit program that grants consumers access to affordable medications across the country.
Under the agreement, PharmcoRx locations will be featured as participating pharmacies in the Team Cuban Card provider directory. The pharmacy chain will actively market its acceptance of the program to its existing customer base and within its network of local clinics and healthcare practices.
Pamela Roberts, Chief Operating Officer of Progressive Care, expressed enthusiasm about the expansion, stating, “Through our inclusion in the Team Cuban Card provider network, we are quickly able to expand our PharmcoRx pharmacy offerings by providing consumers with increased access to medications at a significantly reduced cost.” Roberts highlighted the collaboration as part of the company’s broader mission to positively impact the health of its customers.
The Team Cuban Card program has garnered praise for its convenience, enabling users to obtain their prescriptions locally on the same day, at prices consistent with Cost Plus Drugs’ commitment to affordability. Dr. Alex Oshmyansky, co-founder and CEO of Cost Plus Drugs, expressed excitement about adding PharmcoRx as an option for consumers.
PharmcoRx’s partnership with the Mark Cuban Cost Plus Drug Company aligns with Progressive Care’s commitment to expanding its pharmacy service offerings and outreach initiatives. The collaboration not only enhances customer accessibility to cost-effective medications but also strengthens PharmcoRx’s position as a trusted healthcare provider. The agreement is indicative of the ongoing efforts within the healthcare industry to create innovative solutions that positively impact patient well-being.
For further information, investors can contact Michael Glickman of MWGCO, Inc. at 917-397-2272 or via email at mike@mwgco.net.
It’s worth noting that the information provided in the report may be subject to change based on the dynamic nature of the healthcare industry and business developments.
